8
Oct
2024

i+Med S. Coop.

Exhibitor at CPHI Milan 2024 stand 16F63, Finished Dosage Formulations
About Us

i+Med is a pharmaceutical laboratory, manufacturer and marketer of high value-added medical devices. A world-leading scientific cooperative in the development of smart nanohydrogels and controlled release systems for active substances and drugs.

The laboratory, located in Vitoria-Gasteiz, Spain, focuses on the development and manufacture of its own products as well as third party development under its controlled release technologies. We offer our exclusive ADAPTEK technology for customised developments and active vehicleisation.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • ES
  • 2018
    On CPHI since
  • 3
    Certificates
  • 100 - 249
    Employees
Company types
CMO/CDMO
Contract Service
Distributor/Import Export
Manufacturer/Innovator
OTC
Pharmaceutical company
Primary activities
Contract Manufacturer
Medical Devices
OTC
Out-licensing specialist
Pharmaceutical Company (innovator finished products)
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2024
  • 08 Oct 2024 - 10 Oct 2024
  • Fiera Milano, Italy
  • Visit us at stand 16F63, Finished Dosage Formulations

Products Featured at CPHI Milan 2024

  • ADAPTEK® TECHNOLOGY

    Product ADAPTEK® TECHNOLOGY

    ADAPTEK® TECHNOLOGY is the general name for our 4 international patents and expertise in nanotechnology and controlled release systems.This is a transversal technology that allows to develop customized biopolymeric nanohydrogels, allowing the load with different API (drugs, vitamins, growth factors, etc.)....
  • OpHLINE - Ophthalmic Viscosurgical Devices (HA 1,4%/2%/3%)

    Product OpHLINE - Ophthalmic Viscosurgical Devices (HA 1,4%/2%/3%)

    OpHLINE is an ophthalmic viscosurgical devise (OVD) indicated as a coadjuvant during surgical procedures, involving the anterior chamber of the eye, especially in cataract surgery, including the extraction of the lens and the insertion of intraocular lenses.
    OpHLINE is available in 3 models ...
  • TrHCROSS - Joint injections (cross-linked HA 2%)

    Product TrHCROSS - Joint injections (cross-linked HA 2%)

    TrHCROSS 2% is a biocompatible hydrogel of cross-linked sodium hyaluronate obtained by biofermentation. This is a single injection, designed to relieve joint pain in osteoarthritis by replacing natural joint fluid and replenishing lubricating and shock-absorbing functions.

    Properties
    ...
  • BtHCROSS - Dermal filler (cross-linked HA 1,5%/1,75%/2%)

    Product BtHCROSS - Dermal filler (cross-linked HA 1,5%/1,75%/2%)

    BtHCROSS is a biocompatible cross-linked hyaluronic acid hydrogel intended as a dermatological treatment for aesthetic purposes. It is administered by intradermal injection and designed to restore and correct facial volumes and fill wrinkles and folds.
    Depending on the depth of the wrinkles an...
  • DayDrop - eye drops with the sustained-release system of ectoine

    Product DayDrop - eye drops with the sustained-release system of ectoine

    DayDrop is an ophthalmic solution with sustained release of ectoine, indicated to alleviate the ocular dryness and irritation produced by environmental factors (wind, dust, air conditioning, dry heat), prolonged use of screens or contact lenses and some pathologies that present the above mentioned symp...

i+Med S. Coop. Resources (1)

  • i+Med Company profile

    Brochure i+Med Company profile

    i+Med is a biotech company formed by highly qualified personnel, focused on the R&D and manufacture of new products for third parties. Our ADAPTEK® TECHNOLOGY enables the development of customized biopolymeric nanohydrogels, allowing the load with different API (drugs, vitamins, growth factors, etc.). These intelligent nanoparticles could be programmed to respond to external stimulus (E.g. pH or t˚) that allow the controlled release of APIs. As a result, we can develop high added value and differentiated products that provide our customers with a key competitive advantage in t...